Cormedix Inc is a biopharmaceutical company focused on developing innovative therapies aimed at improving the lives of patients with serious medical conditions
The company primarily concentrates on treatments for infections related to catheter use and other healthcare-associated infections. Cormedix is dedicated to advancing its proprietary product candidates through clinical trials and regulatory pathways, with an emphasis on addressing unmet medical needs in the fields of nephrology and infectious diseases. Through its research and development efforts, Cormedix aims to provide effective and safe therapeutic solutions that enhance patient outcomes.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSETGT) jumped during Wednesday’s session after the company reported better-than-expected third-quarter financial results.
Shares of CorMedix Inc. (NASDAQCRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third quarter, versus market expectations for a loss of 21 cents per share.
